BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005;25:1079-90. [PMID: 16343056 DOI: 10.1111/j.1478-3231.2005.01163.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Harras F, Sheta el S, Shehata M, El Saadany S, Selim M, Mansour L. Endoscopic band ligation plus argon plasma coagulation versus scleroligation for eradication of esophageal varices. J Gastroenterol Hepatol. 2010;25:1058-1065. [PMID: 20594219 DOI: 10.1111/j.1440-1746.2010.06265.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
2 Fukuda T, Narahara Y, Kanazawa H, Matsushita Y, Kidokoro H, Itokawa N, Kondo C, Atsukawa M, Nakatsuka K, Sakamoto C. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis. J Gastroenterol Hepatol. 2014;29:325-329. [PMID: 24033356 DOI: 10.1111/jgh.12360] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
3 Blanco-Rivero J, Aller MA, Arias J, Ferrer M, Balfagón G. Long-term portal hypertension increases the vasodilator response to acetylcholine in rat aorta: role of prostaglandin I2. Clin Sci (Lond). 2009;117:365-374. [PMID: 19331646 DOI: 10.1042/cs20080499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Aller MA, Arias JL, Cruz A, Arias J. Inflammation: a way to understanding the evolution of portal hypertension. Theor Biol Med Model 2007;4:44. [PMID: 17999758 DOI: 10.1186/1742-4682-4-44] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
5 Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, Pirenne J, Nevens F, Roskams T. Clinicopathological Features of Focal Nodular Hyperplasia-Like Nodules in 130 Cirrhotic Explant Livers. Am J Gastroenterology 2006;101:2341-6. [DOI: 10.1111/j.1572-0241.2006.00783.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
6 Li X, Jiang T, Gao J. Endoscopic variceal ligation combined with argon plasma coagulation versus ligation alone for the secondary prophylaxis of variceal bleeding: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2017;29:621-8. [DOI: 10.1097/meg.0000000000000861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
7 Van der Graaff D, Kwanten WJ, Couturier FJ, Govaerts JS, Verlinden W, Brosius I, D'Hondt M, Driessen A, De Winter BY, De Man JG, Michielsen PP, Francque SM. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Lab Invest 2018;98:1263-75. [PMID: 29326427 DOI: 10.1038/s41374-017-0018-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
8 Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108. [PMID: 16859530 DOI: 10.1186/cc4455] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Königshofer P, Brusilovskaya K, Schwabl P, Podesser BK, Trauner M, Reiberger T. Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. J Vis Exp 2018. [PMID: 30124644 DOI: 10.3791/57261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 He XJ, Huang TZ, Wang PJ, Peng XC, Li WC, Wang J, Tang J, Feng N, Yu MH. Morphological and biomechanical remodeling of the hepatic portal vein in a swine model of portal hypertension. Ann Vasc Surg. 2012;26:259-267. [PMID: 22192237 DOI: 10.1016/j.avsg.2011.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
11 Verbeke L, Nevens F, Laleman W. Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care 2011;15:233. [PMID: 22104633 DOI: 10.1186/cc10424] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
12 Cornelis T, Claes K, Gillard P, Nijs E, Roskams T, Lombaerts R, Nevens F, Cassiman D. Cholestatic liver disease in long-term infantile nephropathic cystinosis. Journal of Gastroenterology and Hepatology 2008;23:e428-31. [DOI: 10.1111/j.1440-1746.2008.05312.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Tung HC, Lee FY, Wang SS, Tsai MH, Lee JY, Huo TI, Huang HC, Chuang CL, Lin HC, Lee SD. The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis. PLoS One 2015;10:e0124654. [PMID: 25933224 DOI: 10.1371/journal.pone.0124654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
14 Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Jin W, Kwon YH, Shin MK, Yoo TM, Kang JH, Park CS. Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers. Life Sci 2009;85:281-90. [PMID: 19527736 DOI: 10.1016/j.lfs.2009.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
15 Van Landeghem L, Laleman W, Vander Elst I, Zeegers M, van Pelt J, Cassiman D, Nevens F. Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int 2009;29:650-60. [PMID: 18795901 DOI: 10.1111/j.1478-3231.2008.01857.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
16 Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132:709-719. [PMID: 17258737 DOI: 10.1053/j.gastro.2006.12.041] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
17 Eisinger K, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer MN, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43:926-932. [PMID: 23855493 DOI: 10.1111/eci.12122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
18 Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J 2019;7:850-8. [PMID: 31316789 DOI: 10.1177/2050640619840199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Baffy G. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2018;63:563-76. [DOI: 10.1007/s10620-017-4903-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
20 Feng AC, Fan HL, Chen TW, Hsieh CB. Hepatic hemodynamic changes during liver transplantation: A review. World J Gastroenterol 2014; 20(32): 11131-11141 [PMID: 25170200 DOI: 10.3748/wjg.v20.i32.11131] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
21 Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177-186. [PMID: 24217347 DOI: 10.1038/nrgastro.2013.210] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 15.8] [Reference Citation Analysis]
22 Gitto S, Guarneri V, Sartini A, Andreone P. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert Rev Gastroenterol Hepatol 2018;12:165-71. [PMID: 29082798 DOI: 10.1080/17474124.2018.1399060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Møller S, Stauber RE. Does local sympathetic atrophy contribute to splanchnic vasodilation in portal hypertension? Liver Int 2010;30:499-501. [PMID: 20158609 DOI: 10.1111/j.1478-3231.2010.02206.x] [Reference Citation Analysis]
24 Sakamoto Y, Sakai M, Sato K, Watari T. Plasma renin activity and aldosterone concentration in dogs with acquired portosystemic collaterals. J Vet Intern Med 2020;34:139-44. [PMID: 31729111 DOI: 10.1111/jvim.15661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011;5:523-537; quiz 537. [PMID: 21780899 DOI: 10.1586/egh.11.47] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
26 Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. J Viral Hepat 2017;24:280-6. [DOI: 10.1111/jvh.12641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
27 Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Michielsen P, Van Gaal L. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. Int J Obes (Lond). 2011;35:270-278. [PMID: 20661251 DOI: 10.1038/ijo.2010.134] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
28 Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, Rössle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis 2015;47:144-50. [PMID: 25483910 DOI: 10.1016/j.dld.2014.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
29 Coll M, Martell M, Raurell I, Ezkurdia N, Cuenca S, Hernández-Losa J, Esteban R, Guardia J, Bosch J, Genescà J. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int 2010;30:593-602. [PMID: 19968782 DOI: 10.1111/j.1478-3231.2009.02176.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
30 Laleman W. Hemodynamic effects of albumin dialysis in patients with liver failure: for better or for worse? Ther Apher Dial. 2009;13:384-392. [PMID: 19788454 DOI: 10.1111/j.1744-9987.2009.00756.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
31 Guerra-ruiz A, Casafont F, Cobo M, Terã¡n A, de-la-Peña J, Estebanez A, Pons-romero F. Increased bactericidal/permeability increasing protein in patients with cirrhosis. Liver International 2010;30:94-101. [DOI: 10.1111/j.1478-3231.2009.02121.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
32 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
33 Ayabe S, Murata T, Maruyama T, Hori M, Ozaki H. Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors. Br J Pharmacol 2009;156:835-45. [PMID: 19239477 DOI: 10.1111/j.1476-5381.2008.00051.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
34 Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med 2020;20:289-97. [PMID: 32078718 DOI: 10.1007/s10238-020-00617-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Gaskari SA, Liu H, D'Mello C, Kunos G, Lee SS. Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol 2015;62:1272-7. [PMID: 25640062 DOI: 10.1016/j.jhep.2015.01.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
36 Giuffrè M, Macor D, Masutti F, Abazia C, Tinè F, Patti R, Buonocore MR, Colombo A, Visintin A, Campigotto M, Crocè LS. Evaluation of spleen stiffness in healthy volunteers using point shear wave elastography. Ann Hepatol 2019;18:736-41. [PMID: 31054978 DOI: 10.1016/j.aohep.2019.03.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
37 Dadamio J, Van den Velde S, Laleman W, Van Hee P, Coucke W, Nevens F, Quirynen M. Breath biomarkers of liver cirrhosis. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;905:17-22. [PMID: 22921634 DOI: 10.1016/j.jchromb.2012.07.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
38 Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol 2015; 7(3): 443-459 [PMID: 25848469 DOI: 10.4254/wjh.v7.i3.443] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
39 Liu DJ, Chen W, Huo YM, Liu W, Zhang JF, Hua R, Sun YW. Prostacyclin decreases splanchnic vascular contractility in cirrhotic rats. Hepatobiliary Pancreat Dis Int 2014;13:416-22. [PMID: 25100127 DOI: 10.1016/s1499-3872(14)60270-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Li T, Geng L, Chen X, Miskowiec M, Li X, Dong B. Branched-chain amino acids alleviate nonalcoholic steatohepatitis in rats. Appl Physiol Nutr Metab. 2013;38:836-843. [PMID: 23855271 DOI: 10.1139/apnm-2012-0496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
41 Mukund A, Chalamarla LK, Singla N, Shasthry SM, Sarin SK. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. Eur Radiol 2020;30:3462-72. [PMID: 32048037 DOI: 10.1007/s00330-019-06644-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
42 Oldenburger A, Birk G, Schlepütz M, Broermann A, Stierstorfer B, Pullen SS, Rippmann JF. Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices. Pharmacol Res Perspect 2021;9:e00768. [PMID: 34014044 DOI: 10.1002/prp2.768] [Reference Citation Analysis]
43 Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6:33453. [PMID: 27634375 DOI: 10.1038/srep33453] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 21.0] [Reference Citation Analysis]
44 Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel W. Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. World J Gastroenterol 2018; 24(3): 438-444 [PMID: 29391766 DOI: 10.3748/wjg.v24.i3.438] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 周雯, 杨玲, 胡胜军. Rho蛋白与肝星状细胞. 世界华人消化杂志 2009; 17(24): 2469-2473 [DOI: 10.11569/wcjd.v17.i24.2469] [Reference Citation Analysis]
46 Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, Jung A, Vermeulen W, De Winter B, Pelckmans P. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int. 2010;30:365-375. [PMID: 19840249 DOI: 10.1111/j.1478-3231.2009.02136.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
47 Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol 2015;98:208-13. [PMID: 25595667 DOI: 10.1016/j.yexmp.2015.01.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
48 Wiese S, Hove JD, Møller S. Cardiac imaging in patients with chronic liver disease. Clin Physiol Funct Imaging. 2015; Nov 5. [Epub ahead of print]. [PMID: 26541640 DOI: 10.1111/cpf.12311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
49 van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses 2019;122:188-97. [PMID: 30593409 DOI: 10.1016/j.mehy.2018.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
50 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 21.6] [Reference Citation Analysis]
51 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
52 Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol 2016;6:175-85. [PMID: 27746613 DOI: 10.1016/j.jceh.2016.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
53 Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol. 2010;22:1449-1457. [PMID: 21389796 DOI: 10.1097/meg.0b013e32833f14a1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
54 Llamas MA, Aller MA, Marquina D, Nava MP, Arias J. Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats. Dig Dis Sci. 2010;55:2244-2254. [PMID: 19834810 DOI: 10.1007/s10620-009-1001-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
55 Moan AS. The evaluation of liver dysfunction: when to suspect portal hypertension. JAAPA 2009;22:38-42. [PMID: 19452820 DOI: 10.1097/01720610-200904000-00010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
56 Li Q, Wang J, Lu M, Qiu Y, Lu H. Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes. Front Microbiol 2020;11:583423. [PMID: 33365018 DOI: 10.3389/fmicb.2020.583423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Levitt DG, Levitt MD. Quantitative modeling of the physiology of ascites in portal hypertension. BMC Gastroenterol 2012;12:26. [PMID: 22453061 DOI: 10.1186/1471-230X-12-26] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
58 Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5:90-103. [PMID: 28533907 DOI: 10.1093/gastro/gox011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
59 Bauer S, Eisinger K, Wiest R, Karrasch T, Scherer MN, Farkas S, Aslanidis C, Buechler C. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. Regulatory Peptides 2012;179:10-4. [DOI: 10.1016/j.regpep.2012.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
60 Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, Villalba J, Garcia-Pagan JC, Barrufet M, Jalan R, Brookes J, Thalassinos E, Burroughs AK, Cordoba J, Nevens F; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448-2457. [PMID: 23401201 DOI: 10.1002/hep.26314] [Cited by in Crossref: 143] [Cited by in F6Publishing: 105] [Article Influence: 17.9] [Reference Citation Analysis]
61 Nevens F, Pirenne J. Renal disease in the allograft recipient. Best Pract Res Clin Gastroenterol 2020;46-47:101690. [PMID: 33158468 DOI: 10.1016/j.bpg.2020.101690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Ikegami T, Shimada M, Imura S. Recent role of splenectomy in chronic hepatic disorders. Hepatol Res 2008;38:1159-71. [PMID: 18684129 DOI: 10.1111/j.1872-034X.2008.00384.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
63 Li Y, Liu H, Gaskari SA, Tyberg JV, Lee SS. Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008;295:G252-9. [DOI: 10.1152/ajpgi.00436.2007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
64 Reynaert H, Urbain D, Geerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat Rec (Hoboken). 2008;291:693-698. [PMID: 18484616 DOI: 10.1002/ar.20669] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
65 Begega A, Méndez M, Rubio S, Santín LJ, Aller MA, Arias J, Arias JL. Portal hypertension in 18-month-old rats: memory deficits and brain metabolic activity. Physiol Behav 2010;100:135-42. [PMID: 20184905 DOI: 10.1016/j.physbeh.2010.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
66 Kortgen A, Hetz H, Morgenthaler NG, Paxian G, Hitzler P, Krenn CG, Bauer M. Vasoactive mediators in patients with acute liver failure treated with albumin dialysis. Liver International 2010;30:634-6. [DOI: 10.1111/j.1478-3231.2009.02129.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
67 Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108. [PMID: 16859530 DOI: 10.1186/cc4985] [Cited by in Crossref: 174] [Cited by in F6Publishing: 143] [Article Influence: 11.6] [Reference Citation Analysis]
68 Wiest R, Weiss TS, Danielyan L, Buechler C. Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study. J Clin Med 2021;10:2669. [PMID: 34204545 DOI: 10.3390/jcm10122669] [Reference Citation Analysis]
69 Cavasin MA, Semus H, Pitts K, Peng Y, Sandoval J, Chapo J, Plato CF. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats. Can J Physiol Pharmacol. 2010;88:636-643. [PMID: 20628429 DOI: 10.1139/y10-038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
70 Dourakis SP, Geladari E, Geladari C, Vallianou N. Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased? Curr Cardiol Rev 2021;17:78-84. [PMID: 31072296 DOI: 10.2174/1573403X15666190509084519] [Reference Citation Analysis]
71 Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci 2017;18:E1392. [PMID: 28661458 DOI: 10.3390/ijms18071392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
72 Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, Van Dyck C, D'hondt M, Ramon A, Vermeulen W, De Winter B, Van Marck E, Van Marck V, Pelckmans P, Michielsen P. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 2012;92:1428-39. [DOI: 10.1038/labinvest.2012.103] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
73 Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286-2298. [PMID: 24259407 DOI: 10.1002/hep.26939] [Cited by in Crossref: 153] [Cited by in F6Publishing: 151] [Article Influence: 21.9] [Reference Citation Analysis]
74 Laleman W, Elst IV, Zeegers M, Servaes R, Libbrecht L, Roskams T, Fevery J, Nevens F. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006;36:242-9. [DOI: 10.1111/j.1365-2362.2006.01620.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
75 Singal AK, Kamath PS. Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease. Transl Gastroenterol Hepatol 2019;4:74. [PMID: 31728431 DOI: 10.21037/tgh.2019.09.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
76 Peeters G, Debbaut C, Friebel A, Cornillie P, De Vos WH, Favere K, Vander Elst I, Vandecasteele T, Johann T, Van Hoorebeke L, Monbaliu D, Drasdo D, Hoehme S, Laleman W, Segers P. Quantitative analysis of hepatic macro- and microvascular alterations during cirrhogenesis in the rat. J Anat 2018;232:485-96. [PMID: 29205328 DOI: 10.1111/joa.12760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
77 Aller MA, Arias JL, Arias J. The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension. J Transl Med 2007;5:44. [PMID: 17892556 DOI: 10.1186/1479-5876-5-44] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]